Kanamycin
Kantrex, Klebcil (kanamycin) is a small molecule pharmaceutical. Kanamycin was first approved as Kantrex on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, escherichia coli infections, hepatic encephalopathy, and klebsiella infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA08: Kanamycin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01G: Aminoglycoside antibacterials
— J01GB: Other aminoglycosides in atc
— J01GB04: Kanamycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA24: Kanamycin
Clinical
Clinical Trials
132 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 6 | 5 | 6 | 3 | 4 | 22 |
| Infections | D007239 | EFO_0000544 | — | 4 | 3 | — | 3 | 3 | 12 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 3 | 4 | 1 | 2 | 9 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 4 | 4 | 1 | — | 7 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | 1 | — | 1 | 4 | 7 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 2 | 2 | 3 | 7 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 1 | 1 | 2 | 2 | 6 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 3 | 1 | 1 | 1 | 6 |
| Communicable diseases | D003141 | — | — | 1 | 1 | 1 | 1 | 1 | 5 |
| Blepharitis | D001762 | EFO_0009536 | H01.0 | 1 | — | 2 | 1 | — | 4 |
Show 23 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pseudomonas infections | D011552 | EFO_0001076 | A41.52 | — | 3 | 2 | — | 1 | 6 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 3 | 2 | — | — | 4 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | 2 | — | 2 | 4 |
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | — | 3 | — | — | 3 |
| Prosthesis-related infections | D016459 | EFO_1001406 | — | — | 3 | 1 | — | — | 3 |
| Mycobacterium infections | D009164 | — | A31.9 | — | 2 | 1 | — | — | 2 |
| Critical illness | D016638 | — | — | — | — | 1 | — | 1 | 2 |
| Septic shock | D012772 | — | A48.3 | — | — | 1 | — | 1 | 2 |
| Keratitis | D007634 | — | H16 | — | — | 1 | — | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | — | — | 1 | — | — | 1 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 2 | 3 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 2 | — | — | — | 2 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | — | 1 | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | 1 | — | — | — | 1 |
| Burns | D002056 | — | T30.0 | 1 | 1 | — | — | — | 1 |
| Pseudomonas aeruginosa | D011550 | NCBITaxon_287 | — | — | 1 | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Urologic surgical procedures | D013520 | — | — | — | 1 | — | — | — | 1 |
| Nontuberculous mycobacterium infections | D009165 | EFO_0007461 | A31.9 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | 1 | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | 1 | — | — | — | — | 1 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 1 | — | — | — | — | 1 |
| Rotavirus infections | D012400 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 3 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Astigmatism | D001251 | EFO_0004222 | H52.2 | — | — | — | — | 2 | 2 |
| Gram-negative bacterial infections | D016905 | — | — | — | — | — | — | 2 | 2 |
| Neonatal sepsis | D000071074 | — | — | — | — | — | — | 2 | 2 |
| Fibrosis | D005355 | — | — | — | — | — | — | 1 | 1 |
| Chronic bronchitis | D029481 | — | J42 | — | — | — | — | 1 | 1 |
| Bronchitis | D001991 | — | J40 | — | — | — | — | 1 | 1 |
| Disease susceptibility | D004198 | — | — | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | — | — | 1 | 1 |
Show 68 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Kanamycin |
| INN | kanamycin |
| Description | Kanamycin A is a member of kanamycins. It has a role as a bacterial metabolite. It is a conjugate base of a kanamycin A(4+). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 59-01-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1384 |
| ChEBI ID | 17630 |
| PubChem CID | 6032 |
| DrugBank | DB01172 |
| UNII ID | RUC37XUP2P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 30,092 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
303 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use